Invasive Treatment of Resistant Hypertension: Present and Future

Current Hypertension Reports

Volumn 16, Issue 11, 2014, Pages 1-10

  Ott, Christian ^a   Schmieder, Roland E ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Arteriovenous anastomosis; Carotid baroreceptor stimulation; Carotid body ablation; Catheter; Ethanol; Guidelines; Intervention; Neurovascular compression; Renal artery stenosis; Renal denervation; Treatment resistant hypertension; Ultrasound

Indexed keywords

ANTIHYPERTENSIVE AGENT; NITINOL;

ABLATION THERAPY; ANTIHYPERTENSIVE THERAPY; ARTERIOVENOUS FISTULA; CAROTID BODY; CAROTID SINUS NERVE STIMULATION; ELECTROSTIMULATION; GLOMERULUS FILTRATION RATE; HUMAN; INVASIVE PROCEDURE; KIDNEY ARTERY STENOSIS; KIDNEY DENERVATION; NERVE STIMULATION; NITINOL STENT; NONHUMAN; RENAL ARTERY STENT; RESISTANT HYPERTENSION; REVIEW; ANIMAL; DEVICES; HYPERTENSION; KIDNEY; KIDNEY DISEASES; PROCEDURES; SYMPATHECTOMY; VASCULAR SURGERY; VASCULARIZATION;

ANIMALS; ANTIHYPERTENSIVE AGENTS; HUMANS; HYPERTENSION; KIDNEY; KIDNEY DISEASES; SYMPATHECTOMY; VASCULAR SURGICAL PROCEDURES;

EID: 84930707982     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-014-0488-y     Document Type: Review

References (80)

1. McAdam-Marx C, Ye X, Sung JC, Brixner DI, Kahler KH. Results of a retrospective, observational pilot study using electronic medical records to assess the prevalence and characteristics of patients with resistant hypertension in an ambulatory care setting. Clin Ther. 2009;31(5):1116–23. doi:10.1016/j.clinthera.2009.05.007.
2. de la Sierra A, Segura J, Banegas JR, Gorostidi M, de la Cruz JJ, Armario P, et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension. 2011;57(5):898–902. doi:10.1161/HYPERTENSIONAHA.110.168948. First report of prevalence of true treatment resistant hypertension in a large cohort of patients in usual daily practice.
3. Pimenta E, Calhoun DA. Resistant hypertension: incidence, prevalence, and prognosis. Circulation. 2012;125(13):1594–6. doi:10.1161/CIRCULATIONAHA.112.097345.
4. Judd E, Calhoun DA. Apparent and true resistant hypertension: definition, prevalence and outcomes. J Hum Hypertens. 2014. doi:10.1038/jhh.2013.140.
5. Kumbhani DJ, Steg PG, Cannon CP, Eagle KA, Smith Jr SC, Crowley K, et al. Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis. Eur Heart J. 2013;34(16):1204–14. doi:10.1093/eurheartj/ehs368.
6. Bangalore S, Fayyad R, Laskey R, Demicco DA, Deedwania P, Kostis JB, et al. Prevalence, predictors, and outcomes in treatment-resistant hypertension in patients with coronary disease. Am J Med. 2014;127(1):71–81 e1. doi:10.1016/j.amjmed.2013.07.038.
7. Daemen J, Mahfoud F. Renal denervation: expanding the indication. EuroInterv: J EuroPCR Collab Work Group Interv Cardiol Eur Soc Cardiol. 2013;9(Suppl R):R101–4. doi:10.4244/EIJV9SRA17.
8. Bax L, Woittiez AJ, Kouwenberg HJ, Mali WP, Buskens E, Beek FJ, et al. Stent placement in patients with atherosclerotic renal artery stenosis and impaired renal function: a randomized trial. Ann Intern Med. 2009;150(12):840–8. W150-1.
9. Investigators A, Wheatley K, Ives N, Gray R, Kalra PA, Moss JG, et al. Revascularization versus medical therapy for renal-artery stenosis. N Engl J Med. 2009;361(20):1953–62. doi:10.1056/NEJMoa0905368.
10. Cooper CJ, Murphy TP, Cutlip DE, Jamerson K, Henrich W, Reid DM, et al. Stenting and medical therapy for atherosclerotic renal-artery stenosis. N Engl J Med. 2014;370(1):13–22. doi:10.1056/NEJMoa1310753. Landmark study showing no benefit of renal artery stenting with the respect to the prevention of clinical events when added to multifactorial medical therapy.
11. Baumgartner I, Lerman LO. Renovascular hypertension: screening and modern management. Eur Heart J. 2011;32(13):1590–8. doi:10.1093/eurheartj/ehq510.
12. Textor SC. Issues in renovascular disease and ischemic nephropathy: beyond ASTRAL. Curr Opin Nephrol Hypertens. 2011;20(2):139–45. doi:10.1097/MNH.0b013e328342bb35.
13. De Bruyne B, Manoharan G, Pijls NH, Verhamme K, Madaric J, Bartunek J, et al. Assessment of renal artery stenosis severity by pressure gradient measurements. J Am Coll Cardiol. 2006;48(9):1851–5. doi:10.1016/j.jacc.2006.05.074.
14. Mitri M, Murphy DR, Dobell AR, Karn GM. Cavopulmonary anastomosis in the management of certain irreparable congenital heart lesions. Surgery. 1962;52:513–9.
15. Radermacher J, Chavan A, Bleck J, Vitzthum A, Stoess B, Gebel MJ, et al. Use of Doppler ultrasonography to predict the outcome of therapy for renal-artery stenosis. N Engl J Med. 2001;344(6):410–7. doi:10.1056/NEJM200102083440603.
16. Radermacher J, Ellis S, Haller H. Renal resistance index and progression of renal disease. Hypertension. 2002;39(2 Pt 2):699–703.
17. Trinquart L, Mounier-Vehier C, Sapoval M, Gagnon N, Plouin PF. Efficacy of revascularization for renal artery stenosis caused by fibromuscular dysplasia: a systematic review and meta-analysis. Hypertension. 2010;56(3):525–32. doi:10.1161/HYPERTENSIONAHA.110.152918.
18. Basile DP, Donohoe DL, Roethe K, Mattson DL. Chronic renal hypoxia after acute ischemic injury: effects of L-arginine on hypoxia and secondary damage. Am J Physiol Renal Physiol. 2003;284(2):F338–48. doi:10.1152/ajprenal.00169.2002.
19. Zhou R, Stouffer GA. Is time of renal hypoperfusion an important variable in determining response to renal artery revascularization? JACC Cardiovasc Interv. 2014;7(1):110. doi:10.1016/j.jcin.2013.12.001.
20. Wright JR, Duggal A, Thomas R, Reeve R, Roberts IS, Kalra PA. Clinicopathological correlation in biopsy-proven atherosclerotic nephropathy: implications for renal functional outcome in atherosclerotic renovascular disease. Nephrol Dial Transplant. 2001;16(4):765–70.
21. Jannetta PJ, Segal R, Wolfson Jr SK, Dujovny M, Semba A, Cook EE. Neurogenic hypertension: etiology and surgical treatment. II. Observations in an experimental nonhuman primate model. Ann Surg. 1985;202(2):253–61.
22. Morimoto S, Sasaki S, Miki S, Kawa T, Itoh H, Nakata T, et al. Pulsatile compression of the rostral ventrolateral medulla in hypertension. Hypertension. 1997;29(1 Pt 2):514–8.
23. Yamamoto I, Yamada S, Sato O. Microvascular decompression for hypertension—clinical and experimental study. Neurol Med Chir (Tokyo). 1991;31(1):1–6.
24. Naraghi R, Geiger H, Crnac J, Huk W, Fahlbusch R, Engels G, et al. Posterior fossa neurovascular anomalies in essential hypertension. Lancet. 1994;344(8935):1466–70.
25. Geiger H, Naraghi R, Schobel HP, Frank H, Sterzel RB, Fahlbusch R. Decrease of blood pressure by ventrolateral medullary decompression in essential hypertension. Lancet. 1998;352(9126):446–9.
26. Frank H, Schobel HP, Heusser K, Geiger H, Fahlbusch R, Naraghi R. Long-term results after microvascular decompression in essential hypertension. Stroke. 2001;32(12):2950–5.
27. Frank H, Heusser K, Geiger H, Fahlbusch R, Naraghi R, Schobel HP. Temporary reduction of blood pressure and sympathetic nerve activity in hypertensive patients after microvascular decompression. Stroke. 2009;40(1):47–51. doi:10.1161/STROKEAHA.108.518670.
28. Esler M, Jennings G, Korner P, Willett I, Dudley F, Hasking G, et al. Assessment of human sympathetic nervous system activity from measurements of norepinephrine turnover. Hypertension. 1988;11(1):3–20.
29. DiBona GF, Kopp UC. Neural control of renal function. Physiol Rev. 1997;77(1):75–197.
30. Stella A, Zanchetti A. Functional role of renal afferents. Physiol Rev. 1991;71(3):659–82.
31. Katholi RE. Renal nerves in the pathogenesis of hypertension in experimental animals and humans. Am J Physiol. 1983;245(1):F1–14.
32. Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373(9671):1275–81. doi:10.1016/S0140-6736(09)60566-3.
33. Symplicity HTNI, Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010;376(9756):1903–9. doi:10.1016/S0140-6736(10)62039-9.
34. Brandt MC, Mahfoud F, Reda S, Schirmer SH, Erdmann E, Bohm M, et al. Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J Am Coll Cardiol. 2012;59(10):901–9. doi:10.1016/j.jacc.2011.11.034.
35. Brandt MC, Reda S, Mahfoud F, Lenski M, Bohm M, Hoppe UC. Effects of renal sympathetic denervation on arterial stiffness and central hemodynamics in patients with resistant hypertension. J Am Coll Cardiol. 2012;60(19):1956–65. doi:10.1016/j.jacc.2012.08.959.
36. Ott C, Mahfoud F, Schmid A, Ditting T, Veelken R, Ewen S, et al. Improvement of albuminuria after renal denervation. Int J Cardiol. 2014;173(2):311–5. doi:10.1016/j.ijcard.2014.03.017.
37. Krum H, Schlaich MP, Sobotka PA, Bohm M, Mahfoud F, Rocha-Singh K, et al. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet. 2014;383(9917):622–9. doi:10.1016/S0140-6736(13)62192-3. Final report of the Symplicity HTN-1 study showing a sustained blood pressure fall over 3 years after renal denervation with good safety.
38. Bhatt DL, Kandzari DE, O'Neill WW, D'Agostino R, Flack JM, Katzen BT, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370(15):1393–401. doi:10.1056/NEJMoa1402670. First study comparing renal denervation with a sham-control arm in patients with treatment resistant hypertension.
39. Krause T, Lovibond K, Caulfield M, McCormack T, Williams B, Guideline Development G. Management of hypertension: summary of NICE guidance. BMJ. 2011;343:d4891. doi:10.1136/bmj.d4891.
40. Jung O, Gechter JL, Wunder C, Paulke A, Bartel C, Geiger H, et al. Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens. 2013;31(4):766–74. doi:10.1097/HJH.0b013e32835e2286.
41. Mahfoud F. Reduction in office blood pressure after renal denervation in a large real world patient population with uncontrolled hypertension: interim results from the global SYMPLICITY registry. Presented at the 2014 ACC Scientific Sessions. 2014.
42. Zuern CS, Eick C, Rizas KD, Bauer S, Langer H, Gawaz M, et al. Impaired cardiac baroreflex sensitivity predicts response to renal sympathetic denervation in patients with resistant hypertension. J Am Coll Cardiol. 2013;62(22):2124–30. doi:10.1016/j.jacc.2013.07.046.
43. Dorr O, Liebetrau C, Mollmann H, Gaede L, Troidl C, Rixe J, et al. Soluble fms-like tyrosine kinase-1 and endothelial adhesion molecules (intercellular cell adhesion molecule-1 and vascular cell adhesion molecule-1) as predictive markers for blood pressure reduction after renal sympathetic denervation. Hypertension. 2014;63(5):984–90. doi:10.1161/HYPERTENSIONAHA.113.02266.
44. Worthley SG, Tsioufis CP, Worthley MI, Sinhal A, Chew DP, Meredith IT, et al. Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant hypertension: the EnligHTN I trial. Eur Heart J. 2013;34(28):2132–40. doi:10.1093/eurheartj/eht197. First study reporting safety and efficacy of renal denervation using a multi-electrode system.
45. Papademetriou V, Tsioufis CP, Sinhal A, Chew DP, Meredith IT, Malaiapan Y, et al. Catheter-based renal denervation for resistant hypertension: 12-month results of the EnligHTN I First-in-human study using a multielectrode ablation system. Hypertension. 2014. doi:10.1161/hypertensionaha.114.03605.
46. Walton T, Hardin S, Rothman M, Whitbourn R. Renal artery denervation with a new simultaneous multielectrode catheter for treatment of resistant hypertension: six month results from the Symplicity Spyral First-in-Man Study. EuroPCR. 2014;Euro14A-OP209.
47. Mahfoud F, Mancia G, Schlaich M, Narkiewicz K, Ruilope L, Williams B, et al. Clinical and procedural outcomes of renal artery denervation in real world patients with hypertension: an update from the Global Symplicity Registry. J Am Coll Cardiol. 2013;62(18/Suppl B):B19.
48. Persu A, Jin Y, Azizi M, Baelen M, Volz S, Elvan A, et al. Blood pressure changes after renal denervation at 10 European expert centers. J Hum Hypertens. 2014;28(3):150–6. doi:10.1038/jhh.2013.88.
49. Mahfoud F, Ukena C, Schmieder RE, Cremers B, Rump LC, Vonend O, et al. Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension. Circulation. 2013;128(2):132–40. doi:10.1161/CIRCULATIONAHA.112.000949. Large study showing an improvement of relevant aspects of ambulatory BP monitoring after renal denervation in patients with true-resistant, but not in pseudoresistant hypertension.
50. Vogel B, Kirchberger M, Zeier M, Stoll F, Meder B, Saure D, et al. Renal sympathetic denervation therapy in the real world: results from the Heidelberg registry. Clin Res Cardiol: Off J Ger Card Soc. 2014;103(2):117–24. doi:10.1007/s00392-013-0627-5.
51. Hering D, Mahfoud F, Walton AS, Krum H, Lambert GW, Lambert EA, et al. Renal denervation in moderate to severe CKD. J Am Soc Nephrol: JASN. 2012;23(7):1250–7. doi:10.1681/ASN.2011111062.
52. Ott C, Mahfoud F, Schmid A, Ditting T, Sobotka PA, Veelken R, et al. Renal denervation in moderate treatment-resistant hypertension. J Am Coll Cardiol. 2013;62(20):1880–6. doi:10.1016/j.jacc.2013.06.023. Study showing a substantial blood pressure fall after renal denervation also in patients with moderate treatment-resistant hypertension.
53. Sievert H. On behalf of the REDUCE-HTN Investigators. REDUCE-HTN clinical study: interim 6- and 12-month data. TCT. 2013: oral presentation
54. Verheye S, Ormiston J, Kuck KH, Bergmann M, Sievert H, Torsello G et al. Safety and effectiveness of catheter-based renal sympathetic denervation for the treatment of resistant hypertension: 12-month results of the RAPID study. EuroPCR. 2014:14A-OP208.
55. Zeller T, Andersson B, Bohm M, Kuck KH, Sievert H, Graf T et al. The Paradise renal denervation system: initial clinical results from the ACHIEVE study. EuroPCR. 2014:14A-OP205.
56. Shetty S, Blessing E, Roenschein U, Scheinert D, Diehm N, Jonas M. Renal denervation using the novel therapeutic intra-vascular ultrasound (TIVUS) catheter system—preliminary report of first-in-man safety and performance study. EuroPCR. 2014:14A-OP206.
57. Fischell TA, Vega F, Raju N, Johnson ET, Kent DJ, Ragland RR, et al. Ethanol-mediated perivascular renal sympathetic denervation: preclinical validation of safety and efficacy in a porcine model. EuroInterv: J EuroPCR Collab Work Group Interv Cardiol Eur Soc Cardiol. 2013;9(1):140–7. doi:10.4244/EIJV9I1A20.
58. Streitparth F, Gebauer B, Nickel P, Reinke P, Freyhardt P, Wieners G, et al. Percutaneous computer tomography-guided ethanol sympathicolysis for the treatment of resistant arterial hypertension. Cardiovasc Interv Radiol. 2014;37(2):513–8. doi:10.1007/s00270-014-0850-0.
59. Wang Q, Guo R, Rong S, Yang G, Zhu Q, Jiang Y, et al. Noninvasive renal sympathetic denervation by extracorporeal high-intensity focused ultrasound in a pre-clinical canine model. J Am Coll Cardiol. 2013;61(21):2185–92. doi:10.1016/j.jacc.2013.02.050.
60. Neuzil P, Whitbourn RJ, Starek Z, Esler MD, Brinton T, Gertner M. Optimized external focused ultrasound for renal sympathetic denervation—Wave II trial. J Am Coll Cardiol. 2013;62(18/Suppl B(TCT-61)):B20.
61. Thrasher TN. Effects of chronic baroreceptor unloading on blood pressure in the dog. Am J Physiol Regul Integr Comp Physiol. 2005;288(4):R863–71. doi:10.1152/ajpregu.00489.2004.
62. Scheffers IJ, Kroon AA, Schmidli J, Jordan J, Tordoir JJ, Mohaupt MG, et al. Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study. J Am Coll Cardiol. 2010;56(15):1254–8. doi:10.1016/j.jacc.2010.03.089.
63. Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. JAMA. 1995;273(18):1421–8.
64. Ferguson GG, Eliasziw M, Barr HW, Clagett GP, Barnes RW, Wallace MC, et al. The North American Symptomatic Carotid Endarterectomy Trial: surgical results in 1415 patients. Stroke. 1999;30(9):1751–8.
65. Heusser K, Tank J, Engeli S, Diedrich A, Menne J, Eckert S, et al. Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients. Hypertension. 2010;55(3):619–26. doi:10.1161/HYPERTENSIONAHA.109.140665.
66. Bisognano JD, Bakris G, Nadim MK, Sanchez L, Kroon AA, Schafer J, et al. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled Rheos Pivotal Trial. J Am Coll Cardiol. 2011;58(7):765–73. doi:10.1016/j.jacc.2011.06.008. Large study assessing the efficacy and safety of baroreflex activation therapy in patients with treatment-resistant hypertension.
67. Bakris GL, Nadim MK, Haller H, Lovett EG, Schafer JE, Bisognano JD. Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial. J Am Soc Hypertens. 2012;6(2):152–8. doi:10.1016/j.jash.2012.01.003.
68. Hoppe UC, Brandt MC, Wachter R, Beige J, Rump LC, Kroon AA, et al. Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barostim neo trial. J Am Soc Hypertens. 2012;6(4):270–6. doi:10.1016/j.jash.2012.04.004.
69. Sobotka PA, Osborn JW, Paton JF. Restoring autonomic balance: future therapeutic targets. EuroInterv: J EuroPCR Collab Work Group Interv Cardiol Eur Soc Cardiol. 2013;9(Suppl R):R140-8. doi:10.4244/EIJV9SRA24.
70. Sinski M, Lewandowski J, Przybylski J, Bidiuk J, Abramczyk P, Ciarka A, et al. Tonic activity of carotid body chemoreceptors contributes to the increased sympathetic drive in essential hypertension. Hypertens Res: Off J Jpn Soc Hypertens. 2012;35(5):487–91. doi:10.1038/hr.2011.209.
71. Sinski M, Lewandowski J, Przybylski J, Zalewski P, Symonides B, Abramczyk P, et al. Deactivation of carotid body chemoreceptors by hyperoxia decreases blood pressure in hypertensive patients. Hypertens Res: Off J Jpn Soc Hypertens. 2014. doi:10.1038/hr.2014.91.
72. Abdala AP, McBryde FD, Marina N, Hendy EB, Engelman ZJ, Fudim M, et al. Hypertension is critically dependent on the carotid body input in the spontaneously hypertensive rat. J Physiol. 2012;590(Pt 17):4269–77. doi:10.1113/jphysiol.2012.237800.
73. Nakayama K. Surgical removal of the carotid body for bronchial asthma. Dis Chest. 1961;40:595–604.
74. Faul J, Schoors D, Brouwers S, Scott B, Jerrentrup A, Galvin J, et al. Creation of an iliac arteriovenous shunt lowers blood pressure in chronic obstructive pulmonary disease patients with hypertension. J Vasc Surg. 2014;59(4):1078–83. doi:10.1016/j.jvs.2013.10.069.
75. Cooper CB, Celli B. Venous admixture in COPD: pathophysiology and therapeutic approaches. COPD. 2008;5(6):376–81. doi:10.1080/15412550802522783.
76. Burchell AE, Lobo MD, Sulke N, Sobotka PA, Paton JF. Arteriovenous anastomosis: is this the way to control hypertension? Hypertension. 2014;64(1):6–12. doi:10.1161/hypertensionaha.114.02925. Brief review addressing the pathophysiological mechanism and first findings regarding blood pressure reduction after the creation of a fixed arteriovenous anastomosis.
77. Brouwers S, Dolan E, Galvin A, Dupont A, Schoors D. Creation of an iliofemoral arteriovenous fistula in patients with severe hypertension: a prospective open label multi-center pilot study. J Hypertens. 2013;Supplement(Oral Session 7C.02):e103.
78. McBryde FD, Abdala AP, Hendy EB, Pijacka W, Marvar P, Moraes DJ, et al. The carotid body as a putative therapeutic target for the treatment of neurogenic hypertension. Nat Commun. 2013;4:2395. doi:10.1038/ncomms3395.
79. Foss JD, Fink GD, Osborn JW. Reversal of genetic salt-sensitive hypertension by targeted sympathetic ablation. Hypertension. 2013;61(4):806–11. doi:10.1161/HYPERTENSIONAHA.111.00474.
80. Lohmeier TE, Hildebrandt DA, Dwyer TM, Barrett AM, Irwin ED, Rossing MA, et al. Renal denervation does not abolish sustained baroreflex-mediated reductions in arterial pressure. Hypertension. 2007;49(2):373–9. doi:10.1161/01.HYP.0000253507.56499.bb.